Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04993729 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
A Phase 3 study, sponsored by Tasly Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 853
- Enrollment target
NCT04993729: Completed Phase 3 study, sponsored by Tasly Pharmaceuticals.
NCT04993729 is a Phase 3 study that has completed, run by Tasly Pharmaceuticals. The registered enrollment target is 853 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04993729, a Phase 3 study, has completed, sponsored by Tasly Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 853 participants
- Enrollment target
Study Summary
The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.
Primary Outcome
2018 Lake Louise Scoring System (LLSS) score \[0-12\] will be used in this primary outcome assessment. The higher LLSS scores mean the worse symptoms of AMS. Baseline will be the average of LLSS scores on Day 2 and the one on Day 3 before breakfast.
Interventions
- DRUG T89 capsule
- DRUG Placebo capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 853 participants |
| Start Date | 2021-07-21 |
| Est. Completion | 2023-05-26 |
| Phase | Phase 3 |
What the finished NCT04993729 record still lists
NCT04993729 is an interventional study that assigns participants to a tested intervention. The registered 853 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which T89 capsule is the first listed.
NCT04993729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04993729 about?
NCT04993729 is a clinical study titled "Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)". The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.
What is the current status of trial NCT04993729?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 853 participants. The study started on 2021-07-21. Estimated completion is 2023-05-26.
What interventions are being tested in trial NCT04993729?
The interventions under investigation include: T89 capsule (DRUG), Placebo capsule (DRUG).
Who is sponsoring clinical trial NCT04993729?
This trial is sponsored by Tasly Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04993729's enrollment target sits among peer trials
853 385th of 2000 higher than 1,616 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI